OAG
PRAX icon

Orbis Allan Gray’s Praxis Precision Medicines PRAX Stock Holding History

Orbis Allan Gray’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$512M Sell
1,529,788
-942,692
-38% -$298M 1.76% 20
2026
Q1 		$797M Buy
2,472,480
+1,217,318
+97% +$377M 3.36% 5
2025
Q4 		$370M Buy
+1,255,162
New +$234M 1.55% 25

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Orbis Allan Gray's PRAX Position: Q2 2026 in Review

Orbis Allan Gray reduced its Praxis Precision Medicines (PRAX) stake by 38% in Q2 2026, selling an estimated $298M and leaving 1,529,788 shares worth $512M. The position accounts for 1.76% of the portfolio, ranked #20.

Orbis Allan Gray first reported a position in PRAX in Q4 2025 and has held it in 3 quarters since. The position peaked at $797M in Q1 2026. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Orbis Allan Gray held 1,529,788 shares of Praxis Precision Medicines worth $512M as of Q2 2026.
  • Orbis Allan Gray sold 942,692 Praxis Precision Medicines shares in Q2 2026, an estimated $298M.
  • Praxis Precision Medicines made up 1.76% of Orbis Allan Gray's portfolio in Q2 2026, its #20 holding.
  • Orbis Allan Gray first reported a position in Praxis Precision Medicines in Q4 2025 and has held it in 3 quarters since.
  • Orbis Allan Gray's Praxis Precision Medicines position peaked at $797M in Q1 2026.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Orbis Allan Gray's 13F filing for Q2 2026, filed 14 Aug 2026.